Targeting this axis using antisense oligonucleotides (ASOs) against USP30-AS1 or miR-3646 mimetics may effectively suppress breast cancer stemness and resensitize tumors to conventional chemotherapy. The gene discussed is USP30; the disease is breast carcinoma.